Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | ABL1 | P00519 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | PKM | P14618 | 1/20 | 0.67 |
| ▸ | IDE | P14735 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
| ▸ | HLCS | P50747 | 6/20 | 0.60 |
| ▸ | CA12 | O43570 | 7/20 | 0.54 |
| ▸ | CA1 | P00915 | 7/20 | 0.54 |
| ▸ | CA2 | P00918 | 7/20 | 0.54 |
| ▸ | CA9 | Q16790 | 7/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30058455 | 0.86 | TDP1 (0.64) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL30094823 | 0.85 | HLCS (0.64) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL31364275 | 0.84 | TDP1 (0.72) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL29462121 | 0.84 | TDP1 (0.62) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL29460477 | 0.84 | TDP1 (0.71) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL23011940 | 0.84 | TDP1 (0.71) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL13253736 | 0.84 | TDP1 (0.71) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL12060572 | 0.84 | TDP1 (0.71) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL12116013 | 0.84 | TDP1 (0.71) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL13253967 | 0.84 | TDP1 (0.71) | TDP1MEN1ABL1LMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260139075-A1 | NOVEL BIOTIN-SPECIFIC MONOCLONAL ANTIBODY AND USE THEREOF | ROCHE DIAGNOSTICS OPERATIONS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-12559573-B2 | Biotin-specific monoclonal antibody and use thereof | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20250306016-A1 | NOVEL BIOTIN-SPECIFIC MONOCLONAL ANTIBODY AND USE THEREOF | ROCHE DIAGNOSTICS OPERATIONS INC (US) | 2025-10-02 | — | — | US | disclosed |
| US-20220107309-A1 | NOVEL BIOTIN-SPECIFIC MONOCLONAL ANTIBODY AND USE THEREOF | ROCHE DIAGNOSTICS GMBH (DE) | 2022-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250306016-A1 | NOVEL BIOTIN-SPECIFIC MONOCLONAL ANTIBODY AND USE THEREOF | BTD, IGLV6-57, VSIR | TDP1 4750/4885MEN1 3221/4885ABL1 3134/4885 |
| US-20220107309-A1 | NOVEL BIOTIN-SPECIFIC MONOCLONAL ANTIBODY AND USE THEREOF | BTD, IGLV6-57, VSIR | TDP1 4750/4885MEN1 3221/4885ABL1 3134/4885 |
| US-12559573-B2 | Biotin-specific monoclonal antibody and use thereof | IGLV6-57, LY96, BTD | TDP1 4725/4885MEN1 2651/4885ABL1 1952/4885 |
| US-20260139075-A1 | NOVEL BIOTIN-SPECIFIC MONOCLONAL ANTIBODY AND USE THEREOF | CD22, LY96, F13B | TDP1 4799/4885MEN1 1057/4885ABL1 2440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.